SANOFI patent applications published on March 21st, 2024
Jump to navigation
Jump to search
Summary of the patent applications from SANOFI on March 21st, 2024
Sanofi has recently filed patents for innovative technologies in the fields of medical devices, cancer immunotherapy, protein production, and targeted drug delivery systems. These patents cover a range of applications aimed at improving healthcare outcomes and advancing scientific research.
Summary in bullet points:
- Patents include technologies for temperature control in injection devices, T cell recruiting polypeptides for cancer treatment, methods for determining protein reduction susceptibility, and ligands targeting specific receptors for drug delivery and gene therapy.
- Applications range from medical settings requiring precise temperature control to cancer immunotherapy, biopharmaceutical production, and targeted drug delivery systems.
Notable applications:
- Improved accuracy in drug administration
- Increased patient safety
- Enhanced targeting of T cells to cancer cells
- Potential for personalized medicine applications
- Increased efficiency in protein production
- Enhanced specificity in drug delivery
- Improved efficiency in gene therapy
Contents
- 1 Patent applications for SANOFI on March 21st, 2024
- 1.1 LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES (18503327)
- 1.2 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients ([[SANOFI (18241419). 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients simplified abstract|18241419]])
- 1.3 Injector Device (18475927)
- 1.4 Electronic System for a Drug Delivery Device and Drug Delivery Device (18273707)
- 1.5 Injection Device (18524986)
- 1.6 NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR (18248988)
- 1.7 METHODS OF DETERMINING PROTEIN REDUCTION SUSCEPTABILITY (18241669)
- 1.8 T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY (18267257)
- 1.9 User Device, System and Method for Determining a Threshold Time for an Injection Device to Transition to an Operational Temperature (18039455)
Patent applications for SANOFI on March 21st, 2024
LIPID NANOPARTICLES FOR DELIVERING mRNA VACCINES (18503327)
Main Inventor
Danilo CASIMIRO
6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients ([[SANOFI (18241419). 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients simplified abstract|18241419]])
Main Inventor
Sylvaine CARTOT-COTTON
Injector Device (18475927)
Main Inventor
Beate Franke
Electronic System for a Drug Delivery Device and Drug Delivery Device (18273707)
Main Inventor
Oliver Charles Gazeley
Injection Device (18524986)
Main Inventor
Anthony Paul Morris
NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR (18248988)
Main Inventor
Bettina ELSHORST
METHODS OF DETERMINING PROTEIN REDUCTION SUSCEPTABILITY (18241669)
Main Inventor
Antonio Barberio
T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY (18267257)
Main Inventor
Katrijn Neyt
User Device, System and Method for Determining a Threshold Time for an Injection Device to Transition to an Operational Temperature (18039455)
Main Inventor
Hardy Kietzmann
